Hindsight is 20/20, TC. With current knowledge, it certainly would have been a better decision to take that route. But at that time the rectal exam by the SEC on the K and Covid were unknowns.
Many things certainly did not move in our favor regarding NGIO listing. But let's please move forward from where we are and not play Monday morning quarterback on things that have passed us by.
(3)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links